title: Composition of fibrin glues significantly influences axial vascularization and degradation in isolation chamber model.
abstract: In this study, different fibrin sealants with varying concentrations of the fibrin components were evaluated in terms of matrix degradation and vascularization in the arteriovenous loop (AVL) model of the rat. An AVL was placed in a Teflon isolation chamber filled with 500 μl fibrin gel. The matrix was composed of commercially available fibrin gels, namely Beriplast (Behring GmbH, Marburg, Germany) (group A), Evicel (Omrix Biopharmaceuticals S.A., Somerville, New Jersey, USA) (group B), Tisseel VH S/D (Baxter, Vienna, Austria) with a thrombin concentration of 4 IU/ml and a fibrinogen concentration of 80 mg/ml [Tisseel S F80 (Baxter), group C] and with an fibrinogen concentration of 20 mg/ml [Tisseel S F20 (Baxter), group D]. After 2 and 4 weeks, five constructs per group and time point were investigated using micro-computed tomography, and histological and morphometrical analysis techniques. The aprotinin, factor XIII and thrombin concentration did not affect the degree of clot degradation. An inverse relationship was found between fibrin matrix degradation and sprouting of blood vessels. By reducing the fibrinogen concentration in group D, a significantly decreased construct weight and an increased generation of vascularized connective tissue were detected. There was an inverse relationship between matrix degradation and vascularization detectable. Fibrinogen as the major matrix component showed a significant impact on the matrix properties. Alteration of fibrin gel properties might optimize formation of blood vessels.
authors.affiliation: Department of Plastic and Hand Surgery, University Hospital of Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany. Andreas.Arkudas@uk-erlangen.de
authors.forename: Andreas
authors.initials: A
authors.lastname: Arkudas
authors.forename: Galyna
authors.initials: G
authors.lastname: Pryymachuk
authors.forename: Tobias
authors.initials: T
authors.lastname: Hoereth
authors.forename: Justus P
authors.initials: JP
authors.lastname: Beier
authors.forename: Elias
authors.initials: E
authors.lastname: Polykandriotis
authors.forename: Oliver
authors.initials: O
authors.lastname: Bleiziffer
authors.forename: Heinz
authors.initials: H
authors.lastname: Gulle
authors.forename: Raymund E
authors.initials: RE
authors.lastname: Horch
authors.forename: Ulrich
authors.initials: U
authors.lastname: Kneser
mesh_terms: D000818:Animals; D007611:Aprotinin / Q000494:pharmacology; D001166:Arteriovenous Shunt, Surgical; D005176:Factor XIII / Q000378:metabolism; D015718:Fibrin Tissue Adhesive / Q000737:chemistry* / Q000494:pharmacology; D005340:Fibrinogen / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects; D005782:Gels; D008297:Male; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D051381:Rats; D013917:Thrombin / Q000378:metabolism
chemical_list: D015718:Fibrin Tissue Adhesive; D005782:Gels; D005340:Fibrinogen; D005176:Factor XIII; D007611:Aprotinin; D013917:Thrombin